Source: International Congress 2017 – Lung cancer immunotherapy



Rating:

Share or cite this content

Citations should be made in the following way:
Natasha Leighl (Toronto, Canada). Immune-related adverse effects of checkpoint blockers. International Congress 2017 – Lung cancer immunotherapy

Member's Comments

No comment yet.

Related content which might interest you: Predictors of immunotherapy induced immune-related adverse events Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology Year: 2019 Polymorphisms in genes associated with the development of steroids-induced adverse events Source: Annual Congress 2012 - Gene-environment treatment and asthma Year: 2012 Management of pulmonary toxicity associated with immune checkpoint inhibitors Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019 Year: 2019 The influencing of respiratory adverse effects of enalapril Source: Eur Respir J 2001; 18: Suppl. 33, 264s Year: 2001 The efficacy of immune checkpoint inhibitors in thoracic malignancies Source: Eur Respir Rev, 30 (162) 200387; 10.1183/16000617.0387-2020 Year: 2021 Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis Source: Eur Respir J, 55 (6) 2000038; 10.1183/13993003.00038-2020 Year: 2020 Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF Source: Eur Respir J 2015; 46: 1217-1221 Year: 2015 The clinical benefits of immune checkpoint inhibitors for thymic carcinomas Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 The cardiovascular effects of xanthines and selective PDE inhibitors: a risk–benefit analysis Source: Eur Respir Monogr 2020; 88: 279-286 Year: 2020 Predictive biomarker of immune checkpoint inhibitors efficacy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Detrimental effects of Beta-blockers in COPD Source: Annual Congress 2009 - Beta-blockers may now be beneficial in asthma and COPD Year: 2009 How to manage immune-related adverse effects in lung cancer patients under immunotherapy Source: CME Online 2019 Year: 2018 Efficacy of diltiazem administration on the respiratory adverse effects of enalapril Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002 Management of disease- and therapy-related adverse events Source: ERS Online Course 2019: Essentials of modern lung cancer care – catch up with the latest advances Year: 2019 Late Breaking Abstract - CRAC channel inhibition by RP3128 triggers potent anti-inflammatory effects in COPD or asthmatic patient-derived primary cells Source: International Congress 2018 – New pharmacological strategies in airway diseases Year: 2018 Severe adverse effects of antitubercular drugs and patient management Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Early life events including transgenerational epigenetic effects on respiratory outcomes Source: Eur Respir Monogr 2014; 65: 152-164 Year: 2014